ArticleBritish journal of pharmacology2014
Glabridin inhibits migration and invasion by transcriptional inhibition of matrix metalloproteinase 9 through modulation of NF-κB and AP-1 activity in human liver cancer cells.
Article in British journal of pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 82 citations in OpenAlex.
- Injectable multi-component hydrogel as an inhibitor of choline kinase α achieved the treatment of malignant ascites by inhibiting PI3K/AKT/mTOR signaling pathway.Journal of advanced research · 2026Article
- Review
- Network pharmacology integrated with molecular docking and experimental validation elucidates the therapeutic potential ofFrontiers in oncology · 2025Article
- Biotransformation and Epithelial Toxicity of Prenylated Phenolics from Licorice Roots (Journal of agricultural and food chemistry · 2024Article
- The antitumor mechanisms of glabridin and drug delivery strategies for enhancing its bioavailability.Frontiers in oncology · 2024Review
- The Potential of Glycyrrhiza from "Medicine Food Homology" in the Fight against Digestive System Tumors.Molecules (Basel, Switzerland) · 2023Review
- Synthesis of Bio-Active Silver Nanoparticles against Human Lung Cancer Cell Line (A549) with Little Toxicity to Normal Cell Line (WRL68).Archives of Razi Institute · 2023Article
- Phytochemistry and pharmacology of natural prenylated flavonoids.Archives of pharmacal research · 2023Review
- Review on the Diverse Biological Effects of Glabridin.Drug design, development and therapy · 2023Review
- Biological Screening ofPharmaceuticals (Basel, Switzerland) · 2022Article
- Metabolic Profiling of Glabridin in Rat Plasma, Urine, Bile, and Feces After Intragastric and Intravenous Administration.European journal of drug metabolism and pharmacokinetics · 2022Article
- Structural and Functional Properties of Activator Protein-1 in Cancer and Inflammation.Evidence-based complementary and alternative medicine : eCAM · 2022Review
- Licorice (OncoTargets and therapy · 2022Review
- Pharmacological Effects and Underlying Mechanisms of Licorice-Derived Flavonoids.Evidence-based complementary and alternative medicine : eCAM · 2022Review
- Review
- Heparan sulfate proteoglycans and their modification as promising anticancer targets in hepatocellular carcinoma.Oncology letters · 2021Review
- Curcumin Analogue L48H37 Suppresses Human Osteosarcoma U2OS and MG-63 Cells' Migration and Invasion in Culture by Inhibition of uPA via the JAK/STAT Signaling Pathway.Molecules (Basel, Switzerland) · 2020Article
- Current Perspectives of the Applications of Polyphenols and Flavonoids in Cancer Therapy.Molecules (Basel, Switzerland) · 2020Review
- Solid-State Fermentation ofEvidence-based complementary and alternative medicine : eCAM · 2020Article
- Anticancer activities of phytoconstituents and their liposomal targeting strategies against tumor cells and the microenvironment.Advanced drug delivery reviews · 2020Review
Corrections and comments
- Erratum issuedErratum.2017
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeHigh mortality and morbidity rates for hepatocellular carcinoma in Taiwan primarily result from uncontrolled tumour metastasis. Glabridin, a prenylated isoflavonoid of licorice (Glycyrrhiza glabra) roots, is associated with a wide range of biological properties, such as regulation of energy metabolism, oestrogenic, neuroprotective, anti-osteoporotic and skin whitening. However, the effect of glabridin on the metastasis of tumour cells has not been clarified. EXPERIMENTAL APPROACH: A wound healing model and Boyden chamber assays in vitro were used to determine the effects of glabridin on the migration and invasion of human hepatocellular carcinoma (HHC) cells. Western blot analysis, gelatin zymography, real-time PCR and promoter assays were used to evaluate the inhibitory effects of glabridin on matrix metalloproteinase 9 (MMP9) expression in these cells. KEY
resultsGlabridin significantly inhibited migration/invasion capacities of HCC cells, Huh7 and Sk-Hep-1, cell lines that have low cytotoxicity in vitro, even at high concentrations. Western blot analysis and gelatin zymography showed that glabridin inhibited the expression, activities and protein levels of MMP9 and the phosphorylation of ERK1/2 and JNK1/2. These inhibitory effects were associated with an up-regulation of tissue inhibitor of metalloproteinase-1 and a down-regulation of the transcription factors NF-κB and activator protein 1 signalling pathways. Finally, the administration of glabridin effectively suppressed the tumour formation in the hepatoma xenograft model in vivo. CONCLUSION AND IMPLICATIONS: Glabridin inhibited the invasion of human HCC cells and may have potential as a chemopreventive agent against liver cancer metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.